Blair William & Co. IL Decreases Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Blair William & Co. IL lessened its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 11.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 162,728 shares of the company’s stock after selling 20,796 shares during the period. Blair William & Co. IL owned approximately 0.49% of TransMedics Group worth $24,510,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of TMDX. Wasatch Advisors LP purchased a new position in shares of TransMedics Group in the first quarter worth about $32,162,000. Vaughan Nelson Investment Management L.P. acquired a new position in TransMedics Group in the 2nd quarter worth approximately $39,862,000. First Light Asset Management LLC raised its position in TransMedics Group by 22.0% during the 4th quarter. First Light Asset Management LLC now owns 754,317 shares of the company’s stock worth $59,538,000 after buying an additional 136,217 shares during the last quarter. F M Investments LLC acquired a new stake in TransMedics Group during the 2nd quarter valued at approximately $10,957,000. Finally, Eventide Asset Management LLC lifted its stake in TransMedics Group by 7.4% during the 4th quarter. Eventide Asset Management LLC now owns 994,240 shares of the company’s stock valued at $78,475,000 after acquiring an additional 68,884 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Insiders Place Their Bets

In other TransMedics Group news, Director James R. Tobin sold 20,000 shares of the stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $159.33, for a total transaction of $3,186,600.00. Following the completion of the transaction, the director now owns 173,146 shares of the company’s stock, valued at $27,587,352.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director James R. Tobin sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $159.33, for a total transaction of $3,186,600.00. Following the completion of the sale, the director now directly owns 173,146 shares in the company, valued at $27,587,352.18. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Waleed H. Hassanein sold 8,625 shares of the stock in a transaction on Monday, July 15th. The shares were sold at an average price of $145.17, for a total value of $1,252,091.25. Following the completion of the transaction, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at $8,948,714.31. The disclosure for this sale can be found here. In the last three months, insiders sold 61,247 shares of company stock worth $9,650,880. Corporate insiders own 7.00% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. TD Cowen lifted their price objective on TransMedics Group from $130.00 to $175.00 and gave the company a “buy” rating in a research note on Friday, June 7th. Morgan Stanley lifted their price target on TransMedics Group from $104.00 to $145.00 and gave the company an “equal weight” rating in a research report on Monday, July 15th. Cantor Fitzgerald began coverage on TransMedics Group in a research report on Thursday, June 6th. They issued an “overweight” rating and a $161.00 price objective on the stock. Needham & Company LLC began coverage on shares of TransMedics Group in a research note on Wednesday, August 21st. They set a “buy” rating and a $208.00 price objective on the stock. Finally, Piper Sandler boosted their target price on shares of TransMedics Group from $170.00 to $180.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $171.44.

TransMedics Group Price Performance

TransMedics Group stock opened at $155.96 on Thursday. The stock has a market capitalization of $5.14 billion, a P/E ratio of -458.71 and a beta of 1.99. The company’s fifty day moving average price is $154.75 and its 200 day moving average price is $128.18. The company has a debt-to-equity ratio of 2.67, a quick ratio of 8.48 and a current ratio of 9.37. TransMedics Group, Inc. has a 1 year low of $36.42 and a 1 year high of $177.37.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.21 by $0.14. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The business had revenue of $114.30 million for the quarter, compared to analyst estimates of $98.84 million. During the same quarter last year, the business earned ($0.03) earnings per share. The company’s revenue for the quarter was up 117.7% compared to the same quarter last year. As a group, equities research analysts anticipate that TransMedics Group, Inc. will post 1.23 earnings per share for the current fiscal year.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.